The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

被引：23

作者：

Nicos, Marcin ^{[1
,2
]}

Krawczyk, Pawel ^{[1
]}

Crosetto, Nicola ^{[2
]}

Milanowski, Janusz ^{[1
]}

机构：

[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland

[2] Karolinska Inst, Dept Med Biochem & Biophys, Sci Life Lab, Stockholm, Sweden

来源：

FRONTIERS IN ONCOLOGY | 2020年 / 10卷

关键词：

metastatic non-small cell lung cancer (NSCLC); tumor heterogeneity; immunotherapy; tumor mutation burden; tumor microenvironment; neoantigens; programmed-death 1 (PD-1); programmed-death ligand 1 (PD-L1); TUMOR MUTATIONAL BURDEN; OPEN-LABEL; PD-L1; EXPRESSION; IMMUNOTHERAPY; MICROENVIRONMENT; DOCETAXEL; IMPACT; PEMBROLIZUMAB; NEOANTIGENS; MULTICENTER;

D O I：

10.3389/fonc.2020.569202

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) represent one of the most promising therapeutic approaches in metastatic non-small cell lung cancer (M-NSCLC). Unfortunately, approximately 50-75% of patients do not respond to this treatment modality. Intratumor heterogeneity (ITH) at the genetic and phenotypic level is considered as a major cause of anticancer therapy failure, including resistance to ICIs. Recent observations suggest that spatial heterogeneity in the composition and spatial organization of the tumor microenvironment plays a major role in the response of M-NSCLC patients to ICIs. In this mini review, we first present a brief overview of the use of ICIs in M-NSCLC. We then discuss the role of genetic and non-genetic ITH on the efficacy of ICIs in patients with M-NSCLC.

引用

页数：8

共 89 条

[1] Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Ka ;

Gabrielson, Edward ;

Brock, Malcolm ;

Zahnow, Cynthia ;

Baylin, Stephen B. ;

Scharpf, Rob ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER RESEARCH, 2017, 77

[2] From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer [J].

Angel, Helen ;

Galon, Jerome .

CURRENT OPINION IN IMMUNOLOGY, 2013, 25 (02) :261-267

[3]

[Anonymous], 2015, J CLIN ONCOL S, DOI [10.1200/jco.2015.33.15_suppl.8032, DOI 10.1200/jco.2015.33.15_suppl.8032]

[4] The tumor microenvironment at a glance [J].

Balkwill, Frances R. ;

Capasso, Melania ;

Hagemann, Thorsten .

JOURNAL OF CELL SCIENCE, 2012, 125 (23) :5591-5596

[5] Bone specific immunity and its impact on metastasis [J].

Baschuk, Nikola ;

Rautela, Jay ;

Parker, Belinda S. .

BONEKEY REPORTS, 2015, 4

[6] Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors [J].

Berland, Lea ;

Heeke, Simon ;

Humbert, Olivier ;

Macocco, Adam ;

Long-Mira, Elodie ;

Lassalle, Sandra ;

Lespinet-Fabre, Virginie ;

Lalvee, Salome ;

Bordone, Olivier ;

Cohen, Charlotte ;

Leroy, Sylvie ;

Hofman, Veronique ;

Hofman, Paul ;

Ilie, Marius .

JOURNAL OF THORACIC DISEASE, 2019, 11 :S71-S80

[7] Understanding the tumor immune microenvironment (TIME) for effective therapy [J].

Binnewies, Mikhail ;

Roberts, Edward W. ;

Kersten, Kelly ;

Chan, Vincent ;

Fearon, Douglas F. ;

Merad, Miriam ;

Coussens, Lisa M. ;

Gabrilovich, Dmitry I. ;

Ostrand-Rosenberg, Suzanne ;

Hedrick, Catherine C. ;

Vonderheide, Robert H. ;

Pittet, Mikael J. ;

Jain, Rakesh K. ;

Zou, Weiping ;

Howcroft, T. Kevin ;

Woodhouse, Elisa C. ;

Weinberg, Robert A. ;

Krummel, Matthew F. .

NATURE MEDICINE, 2018, 24 (05) :541-550

[8] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[9] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[10] Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis [J].

Buchhalter, Ivo ;

Rempel, Eugen ;

Endris, Volker ;

Allgaeuer, Michael ;

Neumann, Olaf ;

Volckmar, Anna-Lena ;

Kirchner, Martina ;

Leichsenring, Jonas ;

Lier, Amelie ;

von Winterfeld, Moritz ;

Penzel, Roland ;

Christopoulos, Petros ;

Thomas, Michael ;

Froehling, Stefan ;

Schirmacher, Peter ;

Budczies, Jan ;

Stenzinger, Albrecht .

INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (04) :848-858

← 1 2 3 4 5 6 7 8 9 →